Pharmacological Modulation of the Psychiatric Risk Factor FKBP51 Alters Efficiency of Common Antidepressant Drugs
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Despite a growing body of research over the last few decades, mental disorders, including anxiety disorders or depression, are still one of the most prevalent and hardest to treat health burdens worldwide. Since pharmacological treatment with a single drug is often rather ineffective, approaches such as co-medication with functionally diverse antidepressants (ADs) have been discussed and tried more recently. Besides classical ADs, there is a growing number of candidate targets identified as potential starting points for new treatment methods. One of these candidates, the FK506 binding protein 51 (FKBP51) is linked to a number of psychiatric disorders in humans. In this study, we used SAFit2-a newly developed modulator of FKBP51, which has shown promising results in rodent models for stress-related disorders delivered in a depot formulation. We combined SAFit2 with the commonly prescribed selective serotonin reuptake inhibitor (SSRI) escitalopram and performed basic behavioral characterization in a mouse model. Remarkably, co-application of SAFit2 lowered the efficacy of escitalopram in anxiety-related tests but improved stress coping behavior. Given the fact that mental diseases such as anxiety disorders or depression can be divided into different sub-categories, some of which more or less prone to stress, SAFit2 could indeed be a highly beneficial co-medication in very specific cases. This study could be a first, promising step towards the use of FKBP51 modulators as potent and specific enhancers of AD efficiency for subclasses of patients in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Neural regulation of endocrine and autonomic stress responses
Ulrich-Lai, Y. M., & Herman, J. P. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2647 · Cited by 3,318
Ferrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J. L., Vos, T., & Whiteford, H. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001547 · Cited by 3,115
Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment
Pariante, C. M., & Miller, A. H. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01088-x · Cited by 1,147 · cited 1×
“One of these proteins is the co-chaperone FK506 binding protein 51 (FKBP51), which reduces binding sensitivity of the GR to its ligand (Pratt et al., 2006; Criado-Marrero et al., 2018).”
BackgroundBinder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M. A., et al. (2004) · Nature Genetics · doi:10.1038/ng1479 · Cited by 977
The use of behavioral test batteries: Effects of training history
McIlwain, K. L., Merriweather, M. Y., Yuva-Paylor, L. A., & Paylor, R. (2001) · Physiology & Behavior · doi:10.1016/s0031-9384(01)00528-5 · Cited by 579
Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1173-2 · Cited by 366
Selective inhibitors of the FK506-binding protein 51 by induced fit
Gaali, S., Kirschner, A., Cuboni, S., Hartmann, J., Kozany, C., Balsevich, G., Namendorf, C., Fernandez-Vizarra, P., Sippel, C., Zannas, A. S., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1699 · Cited by 245 · cited 2×
“The scored parameter was the time spent in active escape behavior (struggling; Gaali et al., 2015).”
BackgroundSelf-citationStrawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214 · cited 1×
“Although combining ADs increases the risk of an uncontrolled aggravation of negative side effects, co-medication can improve symptoms in some patients (Thase, 2006).”
BackgroundStress-responsive FKBP51 regulates AKT2-AS160 signaling and metabolic function
Balsevich, G., Häusl, A. S., Meyer, C. W., Karamihalev, S., Feng, X., Pöhlmann, M. L., Dournes, C., Uribe-Marino, A., Santarelli, S., Labermaier, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01783-y · Cited by 134 · cited 3×
“In addition, FKBP51 has been shown to regulate several protein-protein interactions important for cellular function, which may be affected by SAFit2 treatment (Gassen et al., 2015; Balsevich et al., 2017).”
BackgroundMethodSelf-citationPharmacological Inhibition of the Psychiatric Risk Factor FKBP51 Has Anxiolytic Properties
Hartmann, J., Wagner, K. V., Gaali, S., Kirschner, A., Kozany, C., Ruhter, G., Dedic, N., Hausl, A. S., Hoeijmakers, L., Westerholz, S., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4024-14.2015 · Cited by 109 · cited 4×
“From earlier experiments we know that SAFit2 induces (positive) behavioral effects on anxiety-related behavior when used at higher doses or when combined with a stressful challenge (Hartmann et al., 2015).”
BackgroundMethodInfluentialSelf-citationLongitudinal associations between glucocorticoid receptor methylation and late-life depression
Kang, H.-J., Bae, K.-Y., Kim, S.-W., Shin, I.-S., Kim, H.-R., Shin, M.-G., Yoon, J.-S., & Kim, J.-M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.02.004 · Cited by 30
Cited by
Dynamics of ACTH and Cortisol Secretion and Implications for Disease
Lightman, S. L., Birnie, M. T., & Conway-Campbell, B. L. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa002 · Cited by 439
Is the HPA Axis as Target for Depression Outdated, or Is There a New Hope?
Menke, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00101 · Cited by 240
Hähle, A., Merz, S., Meyners, C., & Hausch, F. (2019) · Biomolecules · doi:10.3390/biom9010035 · Cited by 119
Self-citationStructure-Based Design of High-Affinity Macrocyclic FKBP51 Inhibitors
Bauder, M., Meyners, C., Purder, P. L., Merz, S., Sugiarto, W. O., Voll, A. M., Heymann, T., & Hausch, F. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02195 · Cited by 53
Self-citationCruz, B., Vozella, V., Carper, B. A., Xu, J. C., Kirson, D., Hirsch, S., Nolen, T., Bradley, L., Fain, K., Crawford, M., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01497-w · Cited by 25
“SAFit2 was administered 16 h prior to each test [28], and the doses selected were 10 and 20mg/kg based on prior literature [29, 30].”
BackgroundMethod
Metadata
- Authors
- Pöhlmann, M. L., Häusl, A. S., Harbich, D., Balsevich, G., Engelhardt, C., Feng, X., Breitsamer, M., Hausch, F., Winter, G., & Schmidt, M. V.
- Venue
- Frontiers in Behavioral Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-11-12
- Volume
- 12
- Pages
- 262-262
- ISSN
- 1662-5153 (ISSN-L)
- OpenAlex
- W2901118982
- Cited by
- 41
- References
- 12
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.